Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xi-Cheng Wang
Observed names:
X.Q. Wang,
XiCheng Wang,
Xicheng Wang
Institution:
First Affiliated Hospital of Guangdong Pharmaceutical University
Observed institutions:
Zunyi Medical University,
Guangdong Pharmaceutical University,
First Affiliated Hospital of Guangdong Pharmaceutical University,
Lanzhou University Second Hospital,
Lanzhou University
ORCID:
0000-0002-8490-9785
Observed ORCID:
0000-0002-8490-9785
OpenAlex ID:
A5088649157
A 4-miRNAs signature predicts survival in glioblastoma multiforme patients
2017
·
G.Q. Yuan
, N.L. Wei
, et al.
·
Cancer Biomarkers
·
30
Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
·
Clinical Cancer Research
·
9
Role of N6-methyladenosine methylation in nasopharyngeal carcinoma: current insights and future prospective
2024
·
YaYan Zhao
, Jie Li
, et al.
·
Cell Death Discovery
·
8
PDF
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial
2026
·
Byoung Chul Cho
, Rama Balaraman
, et al.
·
Nature Medicine
·
4
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial
2026
·
Zi-Ming Li
, Zhen Zhou
, et al.
·
Cancer Cell
·
2
PDF
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study
2026
·
Ya-Lan Tao
, Dong-Hong Wu
, et al.
·
Nature Cancer
P2.10.15 Mechanistic Study of Osimertinib Combined With Sitravatinibto Overcome Acquired Osimertinib Resistance in Non-Small Cell Lung Cancer
2025
·
X.Q. Wang
, R.P. Li
, et al.
·
Journal of Thoracic Oncology
1767eP Clinical value of cadherin-17 (CA17) as a diagnostic biomarker for gastrointestinal cancers
2025
·
W.C. Cho
, W.S. Yu
, et al.
·
Annals of Oncology
Effective non-surgical treatment of brain-originating metastatic solitary fibrous tumor: A case study
2025
·
Muyun Wu
, Daorong Zhang
, et al.
·
Journal of Radiation Research and Applied Sciences
Data from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
Supplementary Figure S5 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
PDF
Supplementary Table S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
PDF
Supplementary Figure S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
PDF
Supplementary Figure S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
Supplementary Table S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
PDF
Supplementary Figure S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
PDF
Supplementary Table S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
PDF
Supplementary Table S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
PDF
Supplementary Figure S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025
·
Ying Cheng
, Jie Wang
, et al.
PDF
Show more works
View as search
Works count:
19
Citation count:
53
H-index:
4
I10-index:
1
Year
Topic
Type